Select Comfort Corp (NASDAQ: SCSS) 17% LOWER; reported Q4 EPS of $0.22, $0.10 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $220.56 million versus the consensus estimate of $230.04 million. Select Comfort Corp sees FY2013 EPS of $1.65-1.80, versus the consensus of $1.90.
BG Medicine, Inc. (Nasdaq: BGMD) 16% LOWER; announced the sale of 6,000,000 shares of its common stock in an underwritten public offering at a price to the public of $2.00 per share
Synaptics, Inc. (NASDAQ: SYNA) 14% HIGHER; reported Q2 EPS of $0.53, $0.08 better than the analyst estimate of $0.45. Revenue for the quarter came in at $143 million versus the consensus estimate of $137.71 million. Synaptics, Inc. sees Q4 revenue of $140-148 million, versus the consensus of $133.74 million.
Tempur-Pedic International, Inc. (NYSE: TPX) 10% HIGHER; reported Q4 EPS of $0.60, $0.05 better than the analyst estimate of $0.55. Revenue for the quarter came in at $341.1 million versus the consensus estimate of $339.04 million. Tempur-Pedic International, Inc. sees FY2013 EPS of $2.55, versus the consensus of $2.72. Tempur-Pedic International, Inc. sees FY2013 revenue of $1.43 billion, versus the consensus of $1.43 billion.
Oshkosh (NYSE: OSK) 10% HIGHER; reported Q1 EPS of $0.60, $0.29 better than the analyst estimate of $0.31. Revenue for the quarter came in at $1.76 billion versus the consensus estimate of $1.7 billion. Oshkosh sees FY2013 EPS of $2.80-3.05, versus the consensus of $2.63.
Arrowhead Research Corporation (NASDAQ: ARWR) 8% LOWER; announced that it intends to offer units consisting of shares of common stock and warrants in a public offering
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) 7% HIGHER; announced that Threshold’s partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma. The initiation of the Phase 3 MAESTRO study resulted in Threshold earning a $30 million milestone payment from Merck KGaA pursuant to the terms of Threshold’s license and co-development agreement with Merck KGaA, which includes an option for Threshold to co-commercialize in the U.S. MAESTRO stands for TH-302 in the treatment of MetastAtic or unrESectable pancreaTic adenocaRcinOma.
Informatica Corp (NASDAQ: INFA) 7% HIGHER; reported Q4 EPS of $0.41, $0.04 better than the analyst estimate of $0.37. Revenue for the quarter came in at $234.7 million versus the consensus estimate of $217.45 million.
Silicon Graphics International Corp. (NASDAQ: SGI) 7% HIGHER; Sterne Agee upgraded from Neutral to Buy with a price target of $19.00.
Flextronics International Ltd (NASDAQ: FLEX) 6% LOWER; reported Q3 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $6.12 billion versus the consensus estimate of $6 billion. Flextronics International Ltd sees Q4 2013 EPS of $0.11-0.15, versus the consensus of $0.20. Flextronics International Ltd sees Q4 2013 revenue of $5.0-5.3 million, versus the consensus of $5.69 million.
Starbucks Corp (NASDAQ: SBUX) 5% HIGHER; reported Q1 EPS of $0.57, in-line with the analyst estimate of $0.57. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.84 billion. Comps up 6%. Reaffirmed FY2013 guidance.
ResMed, Inc. (NYSE: RMD) 5% HIGHER; reported Q2 EPS of $0.53, $0.02 better than the analyst estimate of $0.51. Revenue for the quarter came in at $376.5 million versus the consensus estimate of $363.76 million.
Autodesk (NASDAQ: ADSK) 4% HIGHER; Goldman Sachs upgraded from Sell to CL with a price target of $45.00 (from $25.00) citing a macro turn.
Halliburton Co. (NYSE: HAL) 4% HIGHER; reported Q4 EPS of $0.67, $0.05 better than the analyst estimate of $0.62. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.07 billion.
8×8 Inc (NASDAQ: EGHT) 4% LOWER; reported Q3 EPS of $0.05, in-line with the analyst estimate of $0.05. Revenue for the quarter came in at $27.3 million versus the consensus estimate of $27.3 million.
E*TRADE Financial Corp. (NASDAQ: ETFC) 4% LOWER; reported Q4 EPS of ($0.65), $0.11 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $468 million versus the consensus estimate of $472.46 million.
Adecoagro S.A. (NYSE: AGRO) 3% LOWER; commenced a public offering of 8,700,000 of its common shares to be sold by certain selling shareholders, subject to market and other conditions.
eBay Inc. (NASDAQ: EBAY) 2% HIGHER; upgraded at Bernstein; New Positive at Susquehanna.
Procter & Gamble Co. (NYSE: PG) 2% HIGHER; reported Q2 EPS of $1.22, $0.11 better than the analyst estimate of $1.11. Revenue for the quarter came in at $22.18 billion versus the consensus estimate of $21.88 billion. Procter & Gamble Co. sees FY2013 EPS of $3.97-4.07, versus prior guidance of $3.80-4.00 and the consensus of $3.98.
United Continental (NYSE: UAL) 2% LOWER; BofA/Merrill Lynch downgraded from Neutral to Underperform.
American Water Works Company, Inc. (NYSE: AWK) 2% LOWER; estimates its 2013 earnings to be in the range of $2.15 to $2.25 per share. The consensus is $2.22.
Microsoft Corp. (NASDAQ: MSFT) 2% LOWER; reported Q2 EPS of $0.76, versus the analyst estimate of $0.75. Revenue for the quarter came in at $21.46 billion versus the consensus estimate of $21.53 billion.
KLA-Tencor Corp (NASDAQ: KLAC) 2% HIGHER; reported Q2 EPS of $0.63, $0.06 better than the analyst estimate of $0.57. Revenue for the quarter came in at $673 million versus the consensus estimate of $634.9 million.
QLogic Corp (NASDAQ: QLGC) 2% HIGHER; reported Q3 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $119.4 million versus the consensus estimate of $115.84 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items – JOIN NOW